Research Article

Association between Recipient IL-15 Genetic Variant and the Prognosis of HBV-Related Hepatocellular Carcinoma after Liver Transplantation

Table 5

Univariate analysis of prognostic factors associated with DFS and OS.

Prognostic factorsDFS (months)OS (months)
Odds ratio (95% CI) valueOdds ratio (95% CI) value

Histologic grade
(0 = differentiated, 1 = undifferentiated)2.093 (1.119–3.915)0.0212.194 (1.162–4.139)0.015
Tumor size (0: <5 cm, 1: ≥5 cm)3.238 (1.818–5.768)<0.0013.253 (1.791–5.910)<0.001
Tumor thrombus (0 = no, 1 = yes)3.893 (2.101–7.015)<0.0013.791 (2.035–7.060)<0.001
Tumor stage (0 = stages I-II, 1 = stage III)3.276 (1.818–5.904)<0.0013.124 (1.695–5.756)<0.001
UCSF criteria (0 = no, 1 = yes)2.769 (1.556–4.927)0.0012.813 (1.552–5.097)0.001
Donor IL-15 rs10519613 genotype
(0 = CC, 1 = CA/AA)2.267 (1.096–4.690)0.0271.778 (0.878–3.601)0.110
Recipient IL-15 rs10519613 genotype
(0 = CC, 1 = CA/AA)3.000 (1.447–6.219)0.0034.005 (1.776–9.030)0.001

DFS: disease-free survival; OS: overall survival; CI: confidence interval.